For example, mutations in KRAS, BRAF, or PIK3CA genes in CRC are often used as biomarkers for selecting patients eligible for targeted therapies, ensuring that the treatment is both relevant and likely to provide benefit to the patient population. The gene discussed is BRAF; the disease is colorectal carcinoma.